$Elevation Oncology (ELEV.US)$
Breakthrough Cancer Drug Shows Promise: First Look at EO-1022 Data for Breast and Lung Cancer

$Elevation Oncology (ELEV.US)$ adding 100 share per drop

$Elevation Oncology (ELEV.US)$ catch the drop, net cash per share 1.x or cash per share 1.9x. well load up and it rebound

$Elevation Oncology (ELEV.US)$ too small of a drop

$Elevation Oncology (ELEV.US)$
Elevation Oncology Halts Cancer Drug Development, Slashes Jobs in Major Strategic Shift

$Elevation Oncology (ELEV.US)$ Elevation Oncology To Discontinue Development Of EO-3021; Continuing To Advance Potentially Differentiated HER3 ADC, EO-1022, Which Utilizes An MMAE Payload And Glycan Site-Specific Conjugation
Benzinga· 2 mins ago
-- Continuing to advance potentially differentiated HER3 ADC, EO-1022, which utilizes an MMAE payload and glycan site-specific conjugation --
-- Plan to present preclinical data for EO-1022 at AACR Annual Meeting 2025 and to file an Investigati...

$Elevation Oncology (ELEV.US)$ big drop then buy !

$Elevation Oncology (ELEV.US)$ Reuters· just
Elevation Oncology to Discontinue Development of Eo-3021; Advancing Eo-1022, While Evaluating Strategic Options

$Elevation Oncology (ELEV.US)$ 🤔

$Elevation Oncology (ELEV.US)$
Can Elevation Oncology's $93M War Chest Transform Cancer Treatment? Key Pipeline Updates